A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Tandem Diabetes Care Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 272,097 shares of TNDM stock, worth $8.98 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
272,097
Previous 205,410 32.47%
Holding current value
$8.98 Million
Previous $8.28 Million 39.41%
% of portfolio
0.06%
Previous 0.04%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$35.21 - $47.3 $2.35 Million - $3.15 Million
66,687 Added 32.47%
272,097 $11.5 Million
Q2 2024

Aug 09, 2024

BUY
$30.43 - $53.43 $1.04 Million - $1.82 Million
34,043 Added 19.87%
205,410 $8.28 Million
Q1 2024

May 09, 2024

SELL
$22.09 - $35.41 $286,175 - $458,736
-12,955 Reduced 7.03%
171,367 $6.07 Million
Q4 2023

Feb 09, 2024

BUY
$14.28 - $31.03 $842,248 - $1.83 Million
58,981 Added 47.06%
184,322 $5.45 Million
Q3 2023

Nov 13, 2023

SELL
$19.33 - $36.22 $2.59 Million - $4.84 Million
-133,742 Reduced 51.62%
125,341 $2.6 Million
Q2 2023

Aug 10, 2023

BUY
$24.18 - $42.46 $285,686 - $501,664
11,815 Added 4.78%
259,083 $6.36 Million
Q1 2023

May 09, 2023

BUY
$35.86 - $46.5 $228,535 - $296,344
6,373 Added 2.65%
247,268 $10 Million
Q4 2022

Feb 10, 2023

BUY
$35.49 - $56.15 $8.03 Million - $12.7 Million
226,171 Added 1536.07%
240,895 $10.8 Million
Q3 2022

Nov 10, 2022

BUY
$43.76 - $68.97 $644,322 - $1.02 Million
14,724 New
14,724 $705,000
Q4 2021

Feb 10, 2022

SELL
$118.18 - $153.21 $2.03 Million - $2.64 Million
-17,200 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$93.51 - $129.4 $1.61 Million - $2.23 Million
17,200 New
17,200 $2.05 Million

Others Institutions Holding TNDM

About TANDEM DIABETES CARE INC


  • Ticker TNDM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 64,221,200
  • Market Cap $2.12B
  • Description
  • Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin c...
More about TNDM
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.